The Week In... Pharma (19-23/08)
  • Posted on: 23/08/2019
  • Category: Industry

The Week In... Pharma (19-23/08)

PM Boris Johnson orders action to crack down on measles, a leaked document forecasts no-deal Brexit shortages, both AbbVie and Celgene receive approval from the FDA, and experts in digital health warn that AI may not be able to keep up with ‘real-world’ medical use. 

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Operations Director, Mark Ward, on 07872 105 540 or email    

On the hunt for a new role, or just curious? 

Visit our candidate page, submit your CV to, or give our offices a ring! 

Leaked no-deal Brexit document forecasts widespread shortages

A leaked government document has revealed the potential risks of a no-deal Brexit, with warnings of delays and shortages of goods coming across the British Channel. 

Boris Johnson orders action to stop measles spread

Prime Minister Boris Johnson is ordering urgent action to ensure that children and young people in Britain are protected against measles.

Celgene scores regulatory win ahead of BMS merger

Celgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA backing its rare bone marrow cancer drug Inrebic.

AbbVie receives FDA approval of RINVOQ™

The FDA has approved AbbVie’s RINVOQ™ (upadacitinib), for the treatment of adults with moderate to severely active rheumatoid arthritis. 

AI may not be able to keep up with real-world medicine use, experts warn

Experts in digital health have published guidance on use of artificial intelligence (AI) in healthcare, warning that the technology may not be able to keep up with how medicines are used in the real world.

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.